Characterizing the post-market safety profile of cemiplimab: a pharmacovigilance study of the FDA adverse events reporting system database

Investigational New Drugs 2026

View at publisher

Authors: Connor Frey

DOI: 10.1007/s10637-026-01628-w

Cited by: 1

References: 15

Fields of Study & Subjects

Pharmacovigilance and Adverse Drug Reactions Biosimilars and Bioanalytical Methods Drug-Induced Adverse Reactions

References 15